After hosting investor meetings with Selecta Biosciences (SELB) management, Cantor Fitzgerald analyst Elaina Merle continues to see a high likelihood that the COMPARE study is positive. The shares are positioned for a 50% to 100% plus move up on statistical significance superiority in COMPARE, Merle tells investors in a research note. Selecta's SEL-212 is well powered to show superiority versus Horizon Therapeutics' (HZNP) Krystexxa in the mid-year readout, says the analyst. Further, she sees further optionality from gene therapy, which the company has guided to enter the clinic this year in collaboration with AskBio. Merle reiterates an Overweight rating on Selecta shares with a $10 price target.